Epilepsy Drugs Market Size To Reach $15.47 Billion By 2030

Epilepsy Drugs Market Growth & Trends

The global epilepsy drugs market size is estimated to reach USD 15.47 billion by 2030, expanding at a CAGR of 5.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness trainingto the physicians through different programs. 

Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period. 

 Request a free sample copy or view report summary: Epilepsy Drugs Market Report

Epilepsy Drugs Market Report Highlights

• Second generation anti-epileptics are expected to be the second-fastest-growing segment. This segment includes Lamotrigine (Lamictal), Levetiracetam (Keppra), Brivaracetam (Briviact), and Perampanel (Fycompa).

• The third generation anti-epileptics segment accounted for the largest revenue share of around 39.7% in 2024. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.

• North America dominated the market with the largest revenue share of around 38.7% in 2024. The high prevalence of epilepsy in the region, with a significant number of people affected by the condition, is a major driving factor for the epilepsy drugs market.

• Asia Pacific epilepsy drugs market is expected to register at a notable CAGR over the forecast period, attributed to the large and diverse population of the region, surging prevalence of epilepsy, and improving healthcare infrastructure.

Epilepsy Drugs Market Segmentation

Grand View Research has segmented the global epilepsy drugs market based on treatment, distribution channel, and region:

Epilepsy Drugs Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• First Generation Anti-epileptics

• Second Generation Anti-epileptics

• Third Generation Anti-epileptics

Epilepsy Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Others

Epilepsy Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • U.K.

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Norway

  • Sweden

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Epilepsy Drugs Market

• UCB S.A.

• Sanofi

• Pfizer, Inc.

• Otsuka America Pharmaceutical, Inc.

• Eisai Co., Ltd.

• Abbott Laboratories, Inc.

• Novartis AG

• GlaxoSmithKline plc

• Sunovion Pharmaceuticals, Inc.

• Jazz Pharmaceuticals plc

• Neurelis, Inc.